Current & Future Role of Anktiva (N-803): Dr. Patrick Soon-Shiong

Anktiva's Mechanism of Action

• 💡 Anktiva (N-803) is an IL-15 receptor superagonist designed to expand and activate natural killer (NK) cells and CD8 T cells, which are crucial for anti-tumor immunity.
• 🧠 Unlike IL-2, which stimulates suppressor cells, IL-15 specifically proliferates killer T-cells and NK cells, making it a potentially more effective and less toxic approach.
• 🔬 This modified IL-15 is long-acting and administered subcutaneously, allowing the patient's body to become a "factory" for these immune cells.

Clinical Efficacy and ALC Restoration

• 📊 Chemotherapy and radiation often deplete NK and T-cells, which are essential for cancer killing, a factor often overlooked in standard blood counts.
• 📈 Restoring the Absolute Lymphocyte Count (ALC) is critical; an ALC below 1,000 indicates significant trouble, and raising it above 1,000-1,200 has been shown to triple median overall survival in lung cancer.
• ✅ Anktiva provides the first ability to stimulate NK cells and increase ALC with a single outpatient injection, turning progressing patients around.

Current Approvals and Trial Data

• 📌 Anktiva is currently approved in the US for non-muscle invasive bladder cancer (NMIBC) and received accelerated approval in Saudi Arabia for non-small cell lung cancer (NSCLC) with immunotherapy.
• 🚀 Randomized trials in first-line lung cancer demonstrated a statistically significant increase in ALC when Anktiva was combined with checkpoint inhibitors.
• 🎯 A single-arm trial in second-line NSCLC patients, who had failed chemo-radiation and were progressing on checkpoint inhibitors, showed a median survival of 25 months, significantly higher than the typical 7-9 months.
• 🌐 The "QUILT" trials across 10 different tumor types also indicated a universal increase in survival with Anktiva.

Minimal Side Effects and Broader Potential

• ⚠️ Anktiva exhibits minimal side effects, primarily a local injection site flare (due to NK cell growth in the skin) and a mild, transient fever, indicating immune activation.
• 🌱 As a natural cytokine, Anktiva activates the body's inherent immune response, making it well-tolerated compared to traditional chemotherapy.
• 💡 Beyond oncology, Anktiva is being explored for conditions like long COVID, HIV, and HPV-related cancers, demonstrating its potential as a universal immune restorative.

Immunotherapy 2.0 and Future Outlook

• 🔥 Anktiva is positioned as "immunotherapy 2.0," aiming to transform "cold" tumors into "hot" by activating the immune system to fight cancer from the "outside in."
• 🔬 The development of allogeneic NK cell therapy (MSANK), derived from Anktiva-stimulated cells, aims to provide readily available "World Bank of Natural Killer Cells" for community oncologists.
• 💪 The speaker emphasizes the undeniable logic of restoring ALC for improved patient outcomes, likening it to restoring hemoglobin or neutrophils, given the established link between lymphopenia and higher mortality.